Loading...
NPI 1518071208 · Henderson, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Khoi Dao is a hematology & oncology physician provider located in Henderson, Nevada. This profile covers 74 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Khoi Dao |
| Address | 10001 S Eastern Ave Ste 108 |
| City | Henderson |
| State | NV |
| ZIP | 89052 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | August 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.2M |
| Medicaid | $7K |
Practice mix aligns with Hematology & Oncology delivery: the provider’s top Medicare revenue driver is J9271 (pembrolizumab) with $550.4K in revenue (49.9% of Medicare revenue) and a second major driver is J0897 (denosumab) with $193.3K (17.5%). The prominence of these biologic/injectable codes together with chemotherapy administration codes such as 96413 (349 claims, $36.6K) and add‑on infusion codes indicates an infusion‑center style oncology practice that delivers systemic cancer therapies and supportive bone‑health agents in office-based settings.
Medicare revenue is highly concentrated in a small set of drugs and visits: the precomputed top 3 Medicare codes by revenue account for 74.1% of this provider’s total Medicare revenue, demonstrating dependence on a few high‑revenue items (notably J9271, J0897, and 99213). On the Medicaid side the precomputed top 3 codes account for 100.0% of Medicaid revenue, indicating Medicaid volume is entirely concentrated in the same low‑complexity office visit code set.
Payer mix is effectively single‑payer dominated: lifetime Medicare revenue is $1.2M versus total Medicaid revenue of $7K, so Medicare is the overwhelmingly dominant payer by scale for this provider. The tiny Medicaid total ($7K) implies very limited Medicaid patient volume relative to Medicare and suggests operations and contracting will be driven by Medicare reimbursement and utilization patterns.
Competitive standing for pembrolizumab and denosumab is mixed: J9271 ranks #866 of 1841 providers nationally (52th percentile; typical, unremarkable volume), indicating a modest national presence for that immunotherapy, while J0897 ranks #1017 of 10057 providers nationally (90th percentile; typical, unremarkable volume), which represents relatively strong denosumab activity versus national peers. By contrast, 99213 for Medicare is an extreme statistical outlier (rank #5028 of 457151, 99th percentile; extreme outlier, far above typical national volume), signaling unusually high office‑visit billing intensity in the Medicare population.
Operational intensity is further supported by very high percentiles on multiple procedure and lab codes: 36415 (rank #990 of 86467, 99th percentile; typical), 85025 (rank #1030 of 32833, 97th percentile; typical), 99212 (rank #3194 of 99011, 97th percentile; notably above typical), and 96372 (rank #1257 of 58224, 98th percentile; notably above typical). These elevated percentiles across venipuncture, CBC, short E&M visits, and injection codes suggest steady throughput of infusion visits and in‑office procedures that complement the provider’s high drug billing.
Medicaid competitive standing is limited: the single Medicaid code on file is 99213 (109 claims, $64 avg paid/claim, $7K revenue), which ranks #1754 of 2476 providers in‑state (29th percentile; typical, unremarkable volume). That in‑state percentile indicates the provider is not a leading Medicaid biller and likely treats few Medicaid patients compared with other Nevada providers.
Longitudinal presence is established: the NPI was enumerated on 2006-08-18 (~20 years ago), indicating roughly two decades of reporting history which supports interpretation of the current code mix as a mature practice pattern rather than a transient spike. Tenure combined with concentrated biologic drug revenue and high visit/administration percentiles points to a stable, infusion‑centric oncology practice where drug utilization and E&M volume are the primary levers affecting financials.
From a payer oversight and contracting perspective, the profile highlights areas to watch and potentially manage: high reliance on a small set of high‑cost biologics (J9271 and J0897) and extreme E&M billing for Medicare (99213 extreme outlier) create focal points for utilization review, site‑of‑care considerations, and drug cost management strategies. The negligible Medicaid revenue suggests any state program interventions would have limited direct financial impact on this provider compared with Medicare-focused initiatives.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
74 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 12,800 | $40 | $550.4K |
| J0897 | Injection, denosumab, 1 mg | 10,740 | $20 | $193.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,110 | $70 | $74.1K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 33,850 | $1 | $67.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 350 | $110 | $36.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 160 | $100 | $16K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 1,950 | $10 | $15.6K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,940 | $10 | $15.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 300 | $50 | $15.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 110 | $120 | $13K |
Showing 1–10 of 74
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 74 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
74 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 19 | 40 | 13,000 | $40 | $625.8K |
| J0897 | 7 | 70 | 3,630 | $20 | $94.6K |
| J0881 | 7 | 30 | 17,400 | $1 | $49.5K |
| 82306 | 26 | 30 | 80 | $30 | $41.9K |
| J9217 | 27 | 40 | 120 | $130 | $23.9K |
| 96413 | 18 | 70 | 210 | $100 | $23.7K |
| 99232 | 1,166 | 1,340 | 140 | $60 | $23.7K |
| 84443 | 29 | 80 | 50 | $20 | $22.7K |
| 80053 | 14 | 100 | 160 | $10 | $22.2K |
| 99214 | 1,421 | 3,610 | 110 | $80 | $19K |
Showing 1–10 of 74
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 110 | $60 | $7K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,754 | 2,480 | 330 | $50 | $107.6K |
Other providers in the same ZIP code as Khoi Dao, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.